Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sparing the liver: targeted chemoembolization meets lenvatinib in liver cancer

NCT ID NCT07827807

Disease control Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are testing whether a liver-sparing form of chemoembolization, called partial TACE, can boost the anti-tumor effects of the drug lenvatinib in people with liver cancer that cannot be removed by surgery. The trial enrolls about 40 adults with hepatocellular carcinoma who are eligible for lenvatinib. Participants receive daily lenvatinib pills plus partial TACE, which targets only the liver segments with the largest tumor burden, within four weeks of starting the drug. The goal is to see whether this combination improves one-year progression-free survival while preserving enough healthy liver function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lenvatinib combined with partial transarterial chemoembolization (TACE)
What this could lead to
If it works, this combination could offer a way to control liver cancer for longer while preserving enough healthy liver to keep patients feeling well.
What could go wrong
This is a small, single-arm phase 2 trial with no comparison group, so any benefit seen may not hold up in larger studies. Combining TACE with lenvatinib can also cause liver toxicity, bleeding, or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Diagnosis of HCC confirmed by histology/cytology or typical imaging features, unsuitable for surgical resection or liver transplantation * Age ≥ 20 years at the time of signing informed consent * ECOG performance status 0-1 * BCLC stage B or C (without main portal vein thrombosis) * Child-Pugh score 5-7 (Class A or B7) within 28 days of registration * Adequate bone marrow, liver, and renal function * Blood pressure adequately controlled * Ability to understand and sign written informed consent Exclusion Criteria: Prior systemic therapy for HCC * Main portal vein thrombosis * Prior locoregional therapy within 4 weeks * Uncontrolled hypertension * Clinically significant cardiovascular disease within 6 months * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.